This prospectively designed, double blinded, placebo-controlled trial has randomised 44 patients (above the 40 prospectively defined number) to receive the Company’s COR-1 HSV-2 vaccine or placebo in a 3:1 ratio.
3:1 ratio though.
a drop of over 90% in the monthly rate versus baseline, page-11
-
- There are more pages in this discussion • 132 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$10.15 |
Change
-0.250(2.40%) |
Mkt cap ! $214.5M | |||
| Open | High | Low | Value | Volume |
| $10.57 | $10.59 | $9.90 | $181.3K | 17.70K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 720 | $10.02 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $10.35 | 3407 | 1 |
View Market Depth
| Last trade - 16.10pm 07/11/2024 (20 minute delay) ? |
| AVR (ASX) Chart |